Estrella Immunopharma, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended December 31, 2023, the second quarter of fiscal 2024 (fiscal year ended June 30). The filing is unaudited. Estrella is a preclinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies; it has no approved products and has generated no product revenue.
Financial position and results
- Revenue and margins: No revenue was reported. Profitability and operating margins are not meaningful for this development-stage business.
- Operating expenses and net loss: For the quarter, R&D expense was $75,459 and G&A expense was $945,165; total operating expenses and net loss were both $1.02 million. For the six months, R&D was $558,925, G&A was $2.33 million, and net loss was $2.89 million.
- Cash flow: Six-month operating cash use was $11.54 million, investing activities provided $4.96 million, and financing activities provided $13.15 million. Cash rose by $6.57 million to $9.05 million at December 31.
- Liquidity and liabilities: Current assets were $9.45 million and current liabilities were $398,733; total liabilities were $398,733. No debt was outstanding at period-end. A $300,000, 12% short-term promissory note issued in September was repaid in October 2023.
- Equity: Stockholders’ equity was $9.05 million, versus a deficit of $11.74 million at June 30, 2023. The change primarily reflects the business combination, financing, and conversion of preferred shares into common stock.
Changes versus prior comparable periods
- Quarterly R&D declined from $2.61 million to $75,459; six-month R&D declined from $5.21 million to $558,925, primarily because Eureka provided fewer services under the Services Agreement.
- Quarterly G&A increased from $148,412 to $945,165; six-month G&A increased from $428,668 to $2.33 million, reflecting public-company and professional costs, accelerated stock compensation upon the business combination, and approximately $0.5 million in executive bonuses.
- Net loss narrowed year over year: $1.02 million versus $2.76 million for the quarter and $2.89 million versus $5.64 million for six months.
- The September 2023 business combination was accounted for as a reverse recapitalization. The company reported approximately $20.1 million in net proceeds from the combination and concurrent financing, then remitted approximately $9.3 million to Eureka in October.
Outlook, risks, and notable items
- The FDA cleared the IND for EB103 in March 2023. Management expected the Phase I/II Starlight-1 trial to begin in the first half of 2024. The filing provides no quantified revenue or earnings guidance and says revenue is not expected for at least the next few years.
- Management expects expenses and operating losses to increase as clinical development advances and public-company costs continue. Management stated available funds and credit line were expected to cover working capital and obligations for at least 12 months; this depends on assumptions and additional financing may be needed.
- A potential White Lion equity line allows purchases of up to $50 million, subject to conditions and issuance limits. Its registration statement became effective December 28, 2023, but no equity-line shares had been issued as of the filing. Issuances reaching 20% of outstanding shares require majority stockholder approval under Nasdaq rules.
- Estrella relies substantially on Eureka for research services, technical support, and clinical-product manufacturing. The filing warns that replacing those capabilities could be difficult. Other risks include clinical and regulatory uncertainty, competition, financing needs, intellectual-property challenges, and uninsured cash balances: $8.78 million of cash was above FDIC coverage limits at December 31.
- Controls: Management concluded disclosure controls were ineffective due to material weaknesses involving accounting expertise, written controls, internal audit/IT functions, and evidence of review and approval. Remediation was planned, with a target of fiscal year-end 2024.
- Subsequent events: On February 9, 2024, the company issued 704,819 shares to each of two PIPE investors, bringing shares outstanding to 36,610,870. A board authorization for up to $1 million of share repurchases was announced January 30; no repurchases had occurred as of February 14, 2024.
- The filing reports no material legal proceedings and no material changes to previously disclosed risk factors. It notes that inflation and geopolitical conflicts could adversely affect results, though their specific effects were not determinable.
Key facts for investors to verify
- Whether the planned EB103 Starlight-1 trial began on the expected schedule, and any subsequent regulatory or clinical updates for EB103 and EB104.
- Actual cash burn after the October payment to Eureka, the remaining cash runway, and whether additional financing is required.
- Progress in remediating the disclosed internal-control weaknesses and whether the stated fiscal 2024 target is met.
- Any White Lion equity-line drawdowns, required stockholder approvals, and resulting dilution; also the terms and potential share impact of the PIPE arrangements.
- Cash concentration and the company’s continuing dependence on Eureka for services and manufacturing.